{"id":339521,"date":"2026-11-04T17:10:28","date_gmt":"2026-11-04T11:40:28","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/marksans-pharma-q2-results-fy27-pat-141-crore\/"},"modified":"2026-11-04T17:10:28","modified_gmt":"2026-11-04T11:40:28","slug":"marksans-pharma-q2-results-fy27-pat-141-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/marksans-pharma-q2-results-fy27-pat-141-crore\/","title":{"rendered":"Marksans Pharma Q2 Results FY27: PAT Jumps 43.83% to Rs 141.31 Cr, Revenue Rs 940.17 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Marksans Pharma Q2 Results FY27 were declared on 4 November 2026, and the quarterly results show revenue of Rs 940.17 Cr, up 30.5% from Rs 720.41 Cr in the same quarter last year. Net profit rose to Rs 141.31 Cr from Rs 98.25 Cr, a YoY growth of 43.83%. Profit grew faster than revenue, which the sections below set out.<\/p>\n<\/div>\n

Marksans Pharma Ltd<\/a> (MARKSANS) Q2 Results FY27 announced on 4 November 2026, covering the company’s financial performance for the July to September quarter. Revenue reached Rs 940.17 Cr and PAT reached Rs 141.31 Cr, against Rs 720.41 Cr and Rs 98.25 Cr a year earlier. With the results date at 4 November 2026, Marksans Pharma Q2 Results FY27 record sharp gains on both lines.<\/p>\n

This results analysis from Univest covers the financial highlights, business drivers, outlook and risks behind Marksans Pharma Q2 Results, keeping attention on the company’s own revenue and net profit. The Financial Highlights table is next.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n